Gaebel W
Rheinische Kliniken Düsseldorf, Psychiatrische Klinik der Heinrich-Heine-Universität Düsseldorf, Germany.
Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S1-6. doi: 10.1097/00004850-199803003-00001.
Treatments that effectively control schizophrenia are now available. The full benefits of these treatments, however, are not being realized, as a result of insufficient compliance by patients and doctors. Patient noncompliance has been largely the result of the shortcomings of conventional antipsychotics (e.g. subjectively distressing side effects), their inappropriate application (e.g. excessively high dosages) and the lack of patient insight into or information about schizophrenia and its treatment. The development of guidelines for drug treatment, the introduction of novel antipsychotics with a better risk-benefit ratio and the implementation of psychosocial interventions all help to improve compliance and treatment outcome. Continued effort needs to be directed towards the educational programmes that have been developed, to ensure that they are used to their maximum potential. Critical treatment issues in the different phases of schizophrenia have been outlined.
目前已有能有效控制精神分裂症的治疗方法。然而，由于患者和医生依从性不足，这些治疗方法的全部益处尚未得到充分实现。患者不依从主要是由于传统抗精神病药物的缺点（如主观上令人痛苦的副作用）、其不恰当应用（如剂量过高）以及患者对精神分裂症及其治疗缺乏认识或了解。制定药物治疗指南、引入风险效益比更佳的新型抗精神病药物以及实施社会心理干预，均有助于提高依从性和治疗效果。需要继续致力于已制定的教育项目，以确保其能发挥最大潜力。文中概述了精神分裂症不同阶段的关键治疗问题。
